PDS Biotechnology
PDSB
57 hedge funds and large institutions have $16.6M invested in PDS Biotechnology in 2024 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 21 reducing their positions, and 24 closing their positions.
386% more call options, than puts
Call options by funds: $1.35M | Put options by funds: $278K
3% more capital invested
Capital invested by funds: $16.1M → $16.6M (+$448K)
3.22% less ownership
Funds ownership: 15% → 11.79% (-3.2%)
26% less funds holding
Funds holding: 77 → 57 (-20)
57% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 21
75% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$376K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$221K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$159K |
| 4 |
SPA
Sherbrooke Park Advisers
White Plains,
New York
|
+$134K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$124K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$930K |
| 2 |
Northern Trust
Chicago,
Illinois
|
-$492K |
| 3 |
Millennium Management
New York
|
-$491K |
| 4 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$418K |
| 5 |
Jane Street
New York
|
-$334K |
PDSB Hedge Fund Activity: Q3 2024 in Review
57 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in PDS Biotechnology (PDSB) for Q3 2024, worth a combined $16.6M — up 2.8% from $16.1M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of PDSB and 6 opened new positions — a net loss of 18 holders — while 21 trimmed existing stakes and 9 added.
The largest buyer was Vanguard Group, adding an estimated $376K. The largest seller was Goldman Sachs, exiting entirely with an estimated $930K sold.
- 57 institutional investors held PDS Biotechnology (PDSB) as of Q3 2024, down from 77 in Q2 2024.
- Funds reported $16.6M of PDS Biotechnology stock for Q3 2024, up 2.8% quarter-over-quarter.
- 6 funds opened new PDS Biotechnology positions in Q3 2024 and 24 closed out, a net change of -18 holders.
- The largest PDS Biotechnology buyer in Q3 2024 was Vanguard Group, an estimated $376K added.
- The largest PDS Biotechnology seller in Q3 2024 was Goldman Sachs, an estimated $930K sold.
Based on aggregated 13F filings for Q3 2024.